Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

18.21
+0.71004.06%
Post-market: 18.220.0100+0.05%19:42 EDT
Volume:3.52M
Turnover:63.35M
Market Cap:1.92B
PE:-13.84
High:18.28
Open:17.28
Low:17.20
Close:17.50
52wk High:25.32
52wk Low:14.68
Shares:105.57M
Float Shares:99.05M
Volume Ratio:1.33
T/O Rate:3.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3161
EPS(LYR):-7.1300
ROE:-9.48%
ROA:-1.13%
PB:1.26
PE(LYR):-2.55

Loading ...

J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)

TIPRANKS
·
May 19

Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says

MT Newswires Live
·
May 15

Sarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target Unchanged

TIPRANKS
·
May 15

Sarepta Therapeutics: Pipeline Binary Risks and Elevidys Uptake Uncertainty Support Neutral Rating Through 2026

TIPRANKS
·
May 11

Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says

MT Newswires Live
·
May 09

Sarepta Therapeutics Shares Down 3.3% After Lower Q1 Sales for Gene Therapy

THOMSON REUTERS
·
May 07

H.C. Wainwright Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)

TIPRANKS
·
May 07

Sarepta Therapeutics (SRPT) Gets a Hold from RBC Capital

TIPRANKS
·
May 07

BUZZ-Sarepta falls on lower quarterly sales for gene therapy

Reuters
·
May 07

Sarepta Therapeutics Shares Slump 13.2% Premarket to $20 After Q1 Results

THOMSON REUTERS
·
May 07

Stock Track | Sarepta Therapeutics Plunges 6.86% Pre-Market on Disappointing Q1 Revenue and Sharp ELEVIDYS Sales Decline

Stock Track
·
May 07

Stock Track | Sarepta Therapeutics Plunges 5.17% After-Hours on Disappointing Q1 Results and Sharp ELEVIDYS Sales Decline

Stock Track
·
May 07

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

Dow Jones
·
May 07

Stock Track | Sarepta Therapeutics Plunges 5.38% After-Hours on Disappointing Q1 Revenue and ELEVIDYS Sales Decline

Stock Track
·
May 07

Sarepta Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 07

Sarepta Therapeutics Q1 revenue falls on lower ELEVIDYS sales

Reuters
·
May 07

Sarepta Therapeutics Fall in Extended Trade Following Results, Last Down 7.6% at $21.27

THOMSON REUTERS
·
May 07

Sarepta Therapeutics Q1 Adj. EPS $3.16 Beats $0.99 Estimate, Sales $730.803M Beat $474.155M Estimate

Benzinga Earnings
·
May 07

Sarepta Q1 net income swings to USD 331 million; revenue slips 2% to USD 730.8 million

Reuters
·
May 07

Sarepta Therapeutics Inc - Q1 2026 Net Product Revenues Total $330.5 Mln

THOMSON REUTERS
·
May 07